RAP 0.00% 20.5¢ raptor resources limited

Ann: ResAppDx-EU for Adult Respiratory Disease Receives CE Mark, page-22

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 2,574 Posts.
    lightbulb Created with Sketch. 4962
    Excellent news under promise and over deliver, I like this strategy. Didn't even realise they had lodged for CE Mark for adults yet just like we never really knew they had lodged for TGA, until we had discovered in that little paragraph announced. BUT CE clearance for adults is a huge step forward in the company's history. This means at market potential just increased dramatically from treating children to now everyone of all ages across Europe!!! Perhaps this is what the companies were waiting for in order to sign on the dotted line, full regulatory clearance of all ages across Europe means now the company can aggressively push forward in its commercialisation strategy, not only push forward but also sign bigger and better agreements. Our company has done a good job holding back on any potential deals to see the full potential come into swing. This is just of course my opinion but it makes perfect sense to me... congratulations to all, we should see a nice Rally on the back of this now...

    Can't wait for the next announcement due in the next couple of trading sessions... could be another very exciting announcement as sleep apnea is a huge market affecting people of all ages, mostly middle-aged to older men and women...

    Bring it on!

    Get the popcorn ready folks, things are going to start heating up from here, NO BS!...

    Cheers

    Red bar
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.